Latest Lead News

Goodman Group has confirmed the dispatch of its 15.00 cents per stapled security distribution for the first half of 2025, maintaining its steady income stream for investors.

WAM Active Limited reported a robust 26.4% increase in its investment portfolio for FY2025, significantly outperforming key benchmarks, while maintaining its fully franked dividend at 6.0 cents per share.

Lincoln Minerals Limited is gearing up for drilling at its Minbrie copper-base metals project in South Australia, while reporting robust financial metrics for its graphite and high purity iron projects.

ASIC has initiated civil proceedings against Equity Trustee Superannuation Limited, alleging failures in due diligence and monitoring related to the Shield Master Fund. Equity Trustees is cooperating with ASIC and supporting affected members while reviewing the claims.

Intelligent Monitoring Group Limited (IMG) reported a 44% revenue surge to $174.9 million in FY25, driven by four key acquisitions and organic growth, while investing heavily in AI-powered video monitoring technology.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

WhiteHawk Limited appoints Giuseppe Porcelli as Chief Strategy Officer to spearhead international growth and strengthen investor confidence, while progressing key U.S. federal cybersecurity contracts.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Victory Metals secures $11.5 million through a strategic placement to accelerate drilling and development at its North Stanmore heavy rare earth project, reinforcing its position as Australia’s leading rare earths explorer.

Calix Limited reported solid FY25 results with 17% growth in product revenue, a 23% cut in operating costs, and an extended 18-month cash runway, while progressing key decarbonisation projects.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.